We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Slight Boost Expected in IVD Industry

By LabMedica International staff writers
Posted on 26 Aug 2013
According to a recent report by healthcare market research publisher Kalorama Information (New York, NY, USA), the US Patient Protection and Affordable Care Act (PPACA) is expected to benefit the IVD and clinical lab test industry to some extent. More...
Sales are expected to rise an extra 1.3% more per year, in the next five years, than would have otherwise been seen without the law.

The Patient Protection and Affordable Care Act (H.R. 3590), passed in 2010 is complex legislation that affects virtually every aspect of health care, and many of its provisions are beginning to take effect now. The overall objective of the PPACA is to expand access to health care coverage for most US citizens and legal residents by requiring individuals to have coverage, and for employers to either provide coverage or pay a penalty that would support coverage from a pool of public funds.

The most significant IVD and clinical lab sales drivers resulting from the PPACA will be an expansion in the number of insured US persons, increased utilization of tests related to nosocomial infections, and new coverage of wellness and prevention programs. Kalorama also noted that the bill contains market restraints as well, and warned that many questions about implementation and future effects remain.

“The reform taketh away from IVD but you could say it ‘giveth’ a little more,” said Bruce Carlson, publisher of Kalorama Information. “Several key provisions of the PPACA, in combination with favorable population demographics, will stimulate IVD product sales. It’s an industry that lives or dies based on test procedure numbers and thus the growth in the number of persons with health care coverage is good news for IVD.”

The Kalorama report contains sales estimates for the historic 2012 period of the IVD market and forecasts are provided through 2022. It then analyzes the impact of various PPACA provisions on the IVD market. The report can be found online (please see Related Links: below).

Kalorama Information, a division of MarketResearch.com, supplies the latest in independent medical market research in diagnostics, biotech, pharmaceuticals, medical devices, and healthcare, as well as a full range of custom research services. Kalorama routinely assist the media with healthcare topics.

Related Links:

Kalorama Information
Report: The Impact of Healthcare Reform (PPACA) On the US IVD Industry



Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Serological Pipet Controller
PIPETBOY GENIUS
New
Specimen Radiography System
TrueView 200 Pro
New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The Volition Nu.Q nucleosome assay runs on the IDS i10 automated analyzer platform (Photo courtesy of VolitionRx)

Groundbreaking Lateral Flow Test Quantifies Nucleosomes in Whole Venous Blood in Minutes

Diagnosing immune disruptions quickly and accurately is crucial in conditions such as sepsis, where timely intervention is critical for patient survival. Traditional testing methods can be slow, expensive,... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.